TMEM37 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, with the in-depth analysis of cellular and molecular immune responses in CML, we identified the active NK cells and anti-PR1 T cells that could help maintain TFR in patients discontinuing TKI treatment.